Bavisant

Cat. No.: HY-14880

CAS No.: 929622-08-2

Molecular Formula: $C_{19}H_{27}N_3O_2$

Molecular Weight: 329.44

Target: Histamine Receptor

Pathway: GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (303.55 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.0355 mL	15.1773 mL	30.3545 mL
	5 mM	0.6071 mL	3.0355 mL	6.0709 mL
	10 mM	0.3035 mL	1.5177 mL	3.0355 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H_3 receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3].

IC_{50} & Target

H_3 receptor

In Vivo

Bavisant increases acetylcholine levels in rat frontal cortex[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ghoshal A, et al. Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents. Eur J Med Chem. 2018 May 25;152:148-159.

[2]. Ghamari N, et al. Histamine H3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther. 2019 Aug;200:69-84.

[3]. Hudkins RL, et al. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem. 2011 Jul 14;54(13):4781-92.

[4]. Weisler RH, et al. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA